

Press Release



Review of Business Operating Structure to Strengthen the Management Foundation

TOKYO, October 1, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo / President, Representative Director: Sohta Yamaguchi, hereinafter the “Company”) has decided to review its business operating structure with the aim of strengthening the management foundation of the entire Group and optimizing the allocation of management resources.

Under its corporate philosophy, “Contribute toward the improvement of people’s health and progress in society through the development of innovative products,” the Group is working to enhance corporate value.

Following the transition to a holding company structure, the Group has decided to consolidate and standardize routine and common operations currently performed by Group companies and at individual locations in order to further enhance the Group’s operating structure. Through these measures, the Group will improve operational efficiency, effectively utilize the management resources generated through the review in its business activities, and strengthen the management foundation of the entire Group.

Consolidation of Sales Offices

As part of this initiative, the Group will consolidate sales support operations and reduce the number of sales office facilities to six locations where the regional divisions are based. This will establish a more efficient operating structure for the sales offices.

The consolidation concerns the closure of sales office facilities and will not involve any changes to the sales organization or sales activities themselves.

Item	Details
Facilities to be retained (6 locations)	Sendai, Saitama, Tokyo (Head Office), Nagoya, Osaka, and Fukuoka
Facilities to be closed (14 locations)	Sapporo, Koriyama, Yokohama, Chiba, Utsunomiya, Niigata, Matsumoto, Kanazawa, Shizuoka, Kyoto, Kobe, Takamatsu, Hiroshima, and Kumamoto
Scheduled implementation date	March 31, 2027

Following the consolidation, the Group will maintain the support functions required for sales activities and pursue efficient operations through the use of shared offices and the

promotion of digital transformation (DX).

Going Forward

The Group will continue to enhance and improve the efficiency of its business operating structure, thereby pursuing sustainable growth for the Group as a whole and enhancing corporate value.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Group Management Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp